Ignite Creation Date:
2024-05-06 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 2:19 PM
Study NCT ID:
NCT05139134
Status:
UNKNOWN
Last Update Posted:
2022-07-29
First Post:
2021-11-09
Brief Title:
Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma
Sponsor:
Sohag University
Organization:
Sohag University
Study Overview
Official Title:
Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma
Status:
UNKNOWN
Status Verified Date:
2022-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Urothelial carcinoma is common malignant tumor worldwide it remains a challenge in the oncology field it is an ideal for research on biomarkers that could identify tumor progression and prognosis CXCL5 have been implicated in progression of many cancers but their significance in urinary bladder UC remains unclear
Detailed Description:
Bladder carcinoma has become a common cancer globally Incidence rates are highest in Europe the United States and Egypt In Egypt bladder carcinoma was considered the third most common tumor Egyptian males have the highest mortality rates UC of the urinary bladder represents about 90 of all bladder cancers
CXCL5 is a chemokine belonging to ELR subgroup It plays an important role in angiogenesis and tumor migration Numerous reports have indicated that CXCL5 plays important roles in cancer progression including cholangiocarcinoma prostate cancer and gastric cancer Studying the IHC expression of CXCL5 in UC to assess its role in tumor cell proliferation migration and spread is needed
CXCL5 is a chemokine belonging to ELR subgroup It plays an important role in angiogenesis and tumor migration Numerous reports have indicated that CXCL5 plays important roles in cancer progression including cholangiocarcinoma prostate cancer and gastric cancer Studying the IHC expression of CXCL5 in UC to assess its role in tumor cell proliferation migration and spread is needed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None